Infinity Pharmaceuticals (INFIQ) 10-K2012 FY Annual report

Filed: 5 Mar 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AbbVie, ACR, adenocarcinoma, advisor, allergen, allergic, ASH, asthma, BID, biochemical, Bloch, bore, breath, Brigham, BRP, Bruton, BTK, cGLP, chest, CLL, Commonwealth, composed, concurrently, contemplation, context, Crohn, customary, diagnostic, diffuse, disability, disappointing, DLBCL, dollar, dysfunction, expiratory, extraordinary, FL, follicular, France, futility, GCP, Germany, headcount, Hodgkin, ibrutinib, indemnification, indolent, installment, Italy, JAK, Japan, Lawrence, leverage, lymphoblastic, mailed, mammalian, mantle, migration, mild, Millenium, mutually, myeloid, negotiated, NeurAxon, NHL, NitroMed, node, nonclinical, noncurrent, outlook, overpaid, overpayment, piggyback, pro, RA, rapamycin, rarest, rata, reallocated, reciprocal, refund, refunded, regular, relaying, remeasured, renegotiation, replicated, resident, resigned, rheumatoid, Rheumatology, scale, Spain, succeed, surface, swelling, Syk, TG, thousand, topline, UK, undertook, underwritten, verify, voluntarily, waived, wheezing, Woman, workforce

Removed: activation, administered, affecting, aid, amortizing, ansamycin, Assistance, assume, ASU, attribute, automatically, basal, binding, binomial, Boston, Bristol, budgeted, calendar, collected, committed, conflicting, consecutive, consistently, contractually, Counsel, desirable, deter, dictate, disposed, disrupting, Dodge, drawn, driven, embryonic, enhanced, ensuing, environment, Esq, exacerbate, exercisable, family, FASB, fatigue, formation, gemcitabine, Gerald, growing, harvest, hindering, Homeownership, hostile, impacting, intention, junior, light, LLP, lump, malignant, natural, naturally, Northeastern, Notwithstanding, opportunity, opt, ovarian, pain, Palmer, partnered, penalty, periodically, pill, plant, plasma, play, poison, premium, prepay, producing, progenitor, Quirk, reacquired, reacquisition, receptor, regained, reoccurrence, revise, salary, Smoothened, steering, stroma, stromal, sum, surgery, sustainable, Swarthmore, systemically, tail, thereto, thereunder, tissue, tolerability, twelve, utilization, vendor, weather, Worker

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

INFIQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-184775, Form S-3 Nos. 333-184184, 333-173534, 333-156246, and Form S-8 Nos. 333-167488, 333-164207, 333-156641, 333-151135, 333-145306, 333-138248 and 333-182005) of Infinity Pharmaceuticals, Inc. and in the related Prospectuses of our reports dated March 5, 2013, with respect to the consolidated financial statements of Infinity Pharmaceuticals, Inc., and the effectiveness of internal control over financial reporting of Infinity Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2012.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 5, 2013